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INTRODUCTION
  The characterization of natural killer (NK) cells initially 
occurred in the 1970s and 1980s as a result of efforts by 
investigators such as Rolf Kiessling and Ronald Heberman. 
It was observed that a certain population of cells, freshly 
isolated from normal, unimmunized hosts, could lyse alloge-
neic tumor cells without sensitization. At the time, these 
cells were just considered to be a population of non-T, 
non-B lymphocytes. After the introduction of modern tech-
nologies such as monoclonal antibody (mAb) production 
technology and flow cytometry, the population has been 
i d e n t i f i e d  a s  N K  c e l l s ,  p h enotypically defined as CD56
＋ 
CD3
−. Nowadays, it is well known that NK cells have a 
role as killer cells as well as immunoregulatory cells secreting 
cytokines and chemokines. Contrary to traditional views, 
NK cells have recently been shown to require a process 
called “licensing” or “education” to acquire full function 
by recognition of self-MHC class I during maturation.
  NK cells are derived from CD34
＋ hematopoietic progeni-
tor cells and have the morphology of large granular 
lymphocytes. They can directly kill target cells via the per-
forin-granzyme pathway, antibody-dependent cellular cy-
totoxicity (ADCC), and death receptor ligand-induced 
apoptosis. Such ligands include tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) and Fas ligand. Human 
NK cells can be classified into two subsets; CD56dim (90%) 
and CD56bright (10%). The CD56dim subset has high cyto-
toxic activity and expresses a low-affinity receptor for the 
constant region of immunoglobulin G, FcγRIIIa (CD16), 
while the CD56bright subset has the capacity to produce 
abundant cytokines.
BALANCE BETWEEN ACTIVATING AND INHIBITORY 
SIGNALS
  It is now well known that NK cell cytotoxicity is tightly 
regulated by a balance between activating and inhibitory 
signals. However, initially NK cells were considered to be 
effector cells with the ability to conduct nonspecific killing 
of tumor target cells. In 1986, Klas Karre and colleagues 
first proposed their “missing self” hypothesis. According 
to this theory, inhibitory receptors (killer cell im-
munoglobulin-like receptor, KIRs) of NK cells specifically 
recognize self-MHC class I molecules expressed by normal 
cells, and this recognition leads to the inhibition of their 
killing activity [1]. If the self-MHC class I molecules on 
normal cells are altered or absent because of viral infection 
or transformation, the inhibitory signal will decrease, lead-
ing to cytotoxic activity against the target cell. Recent studies 
have identified NK cell inhibitory receptors that recognize 
non-MHC-molecule ligands, although the best described 
inhibitory receptors recognize MHC class I molecules [1].
  For many years NK cells were considered to be controlled 
only via inhibitory mechanisms. However, these mecha-
nisms could not fully explain the fact that some MHC-neg-Korean J Hematol 2011;46:3-5.
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Fig. 1. Representative examples of combinatorial approaches of natural killer (NK) cell immunotherapy with chemotherapy, radiation, or 
monoclonal antibody (mAb) therapy. One approach (A) would be to combine NK cell immunotherapy with chemotherapy (e.g., bortezomib), which
downregulates cell surface expression of human leukocyte antigen (HLA) class I on target cells (missing self) and enhances NK cell-mediated lysis
of tumor targets. Another approach (B) is to combine NK cell therapy with radiation therapy, which is known to increase the expression of NK 
activating ligands (e.g., NKG2D ligands) on malignant cells (induced self), thus rendering tumors more susceptible to NK cell cytotoxic activity. The
third approach (C) is to combine NK cell immunotherapy with mAb therapy (e.g., the anti-HER2/neu mAb trastuzumab). NK cells express an 
activating Fc receptor (FcγRIIIa, CD16) that recognizes the constant region of IgG and allows them to kill antibody-coated target cells via 
antibody-dependentcell-mediated cytotoxicity.
ative cells are resistant to an NK cell attack while certain 
NK-susceptible targets express a normal MHC class I 
repertoire. This led to the conclusion that NK cell activation 
requires more than just the absence of inhibitory signals 
and that, ideally, the target must also express specific ligands 
for NK activating receptors [1]. A good example is the 
NKG2D activating receptor that recognizes stress-induced 
self-proteins such as MICA/B and ULBP 1-5, which are 
upregulated in infected or transformed cells. This is known 
as “induced self”. It is now well established that NK cells 
require specific activating signals as well as the absence 
of inhibitory signals in order to exhibit killing activity.
NK CELL-BASED IMMUNOTHERAPY FOR TREATING 
CANCER
  In 1982, Rosenberg and colleagues demonstrated that au-
tologous lymphokine-activated killer (LAK) cells, prepared 
by culturing peripheral blood lymphocytes (PBL) in inter-
leukin-2 (IL-2) for 2-3 days, could lyse freshly isolated autol-
ogous solid tumor cells in vitro. This killing effect was 
predominantly mediated by NK cells [2, 3]. Based on the 
experimental and clinical studies by this group, several clin-
ical trials on LAK cells, mostly in combination with IL-2, 
were performed by the end of the 1990s. Although a clinical 
response rate of about 15-20% was reported, LAK therapy 
in this form was discarded due to its significant toxicity 
and non-superiority to IL-2 therapy alone. The failure of 
these autologous LAK and NK cell-based therapies are ex-
plained by the presence of inhibitory KIRs and their role 
in preventing NK cell killing of “self”-MHC-expressing tu-
mor cells or IL-2-induced expansion of regulatory T cells 
that directly inhibit the NK cell killing effect [2].
  This failure led to the investigation of the use of allogeneic 
NK cells in cellular therapy. In 2002, It was reported that 
KIR-ligand mismatch between patients and their donors 
was associated with improved outcomes in myeloid leuke-
mia after T cell depleted haploidentical hematopoietic stem 
cell transplantation (HCT). They used stem cells or NK 
cells from donors that were mismatched for their KIR ligand 
expression pattern as compared to the MHC profile of the 
host recipient. This created a situation where the newly 
arrived donor NK cells were released from their KIR in-
hibition against tumor cells that lacked the appropriate MHC Korean J Hematol 2011;46:3-5.
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molecules. Additional clinical trials support the association 
between KIR-ligand mismatch and survival advantage after 
unrelated donor HCT when anti-thymocyte globulin is used 
as part of graft versus host disease prophylaxis [3].
  In addition to the use of allogeneic NK cells in the context 
of HCT, adoptive transfer of allogeneic NK cells from hap-
loidentical donor has also been used. In 2005, Miller and 
colleagues showed that haploidentical donor-related NK cell 
infusions expanded in vivo were safe and effective, especially 
in patients with refractory acute myeloid leukemia with 
KIR-ligand mismatched status who received a lympho-
cyte-depleting regimen of cyclophosphamide and fludar-
abine (Hi-Cy/Flu). However, contrary to their initial report, 
in 2008, this group reported that the clinical efficacy of 
the treatment did not correlate with KIR-ligand mismatched 
status [3]. Adoptive transfer protocols are also now using 
NK cell donor lymphocyte infusions after haploidentical 
HCT to consolidate engraftment or adoptively transferred 
NK cells to augment HCT [3]. Recently ex vivo expansion 
techniques for NK cells have undergone marked improve-
ment. Thus, improved clinical outcomes might be antici-
pated if ex vivo expanded NK cells were employed in adop-
tive transfer protocols.
PROMISING COMBINATION OF CHEMO-RADIOTHERAPY 
WITH NK CELL-BASED IMMUNOTHERAPY
  Recently there is some evidence of potential synergistic 
effects of combinational cancer therapies against hemato-
logic malignancies and solid tumors (Fig. 1). One approach 
would be to combine NK cell-based immunotherapy with 
chemotherapy. It was shown that the bortezomib, a protea-
some inhibitor that is clinically approved for the treatment 
of refractory/relapsed myeloma, down-regulates the cell- 
surface expression of HLA class I on target cells and enhances 
natural killer cell-mediated lysis of myeloma tumor targets. 
Moreover, clinically relevant bortezomib concentrations did 
not affect NK-cell function. According to their findings, 
this combination therapy has important therapeutic im-
plications for multiple myeloma and other NK cell-sensitive 
malignancies in the context of adoptively - transferred allo-
geneic and autologous NK cells.
  Another example is combining NK cell therapy with radi-
ation therapy because irradiation-induced tissue injury is 
known to increase the expression of NK activating ligands 
(e.g., NKG2D ligands) on malignant cells, thus rendering 
tumors more susceptible to NK cell cytotoxic activity. Cho 
et al. [4] recently showed that Ewing’s sarcoma cells are 
highly sensitive to expanded allogeneic NK cells. Radiation 
therapy has been shown to significantly enhance the NK 
cell-mediated killing of these tumors in an orthotopic mur-
ine model.
  Another approach is to combine NK cell-based therapy 
with mAb therapy because NK cells express an activating 
Fc receptor that recognizes the constant region of tu-
mor-bound antibodies. This allows NK cells to kill mAb- 
coated target cells through ADCC. Clinical examples of this 
effect include patients with CD20
+ lymphoma who have 
been treated with rituximab (Rituxan
TM) or patients with 
HER2/neu expressing breast cancers who have been treated 
with trastuzumab (Herceptin
TM). Dr. William Carson’s group 
has shown that co-administration of immunomodulatory cyto-
kines (e.g., IL-12) can enhance the effects of anti-tumor 
mAbs via the activation of NK cells in vitro and in the 
context of a phase I trial of IL-12 and trastuzumab [5] and 
a follow-up trial of IL-12 in combination with trastuzumab 
plus paclitaxel for patients with HER2 overexpressing 
cancers.
  In conclusion, NK cell-based immunotherapy is a promis-
ing therapy for solid and hematologic cancers that can poten-
tially be combined with chemotherapy, radiation, or mAb 
therapy.
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